Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability.

Riley TP, Hellman LM, Gee MH, Mendoza JL, Alonso JA, Foley KC, Nishimura MI, Vander Kooi CW, Garcia KC, Baker BM.

Nat Chem Biol. 2018 Oct;14(10):934-942. doi: 10.1038/s41589-018-0130-4. Epub 2018 Sep 17.

PMID:
30224695
2.

Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.

Eby JM, Smith AR, Riley TP, Cosgrove C, Ankney CM, Henning SW, Paulos CM, Garrett-Mayer E, Luiten RM, Nishimura MI, Baker BM, Le Poole IC.

Pigment Cell Melanoma Res. 2018 Jul 15. doi: 10.1111/pcmr.12724. [Epub ahead of print]

PMID:
30009548
3.

Activated human Foxp3+ regulatory T cells produce membrane-bound TNF.

Nelson A, Cunha C, Nishimura MI, Iwashima M.

Cytokine. 2018 Jun 6. pii: S1043-4666(18)30236-9. doi: 10.1016/j.cyto.2018.05.036. [Epub ahead of print]

PMID:
29885993
4.

Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.

Wang F, Bank T, Malnassy G, Arteaga M, Shang N, Dalheim A, Ding X, Cotler SJ, Denning MF, Nishimura MI, Breslin P, Qiu W.

Hepatol Commun. 2018 Apr 17;2(6):732-746. doi: 10.1002/hep4.1181. eCollection 2018 Jun.

5.

Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.

Foley KC, Nishimura MI, Moore TV.

Melanoma Res. 2018 Jun;28(3):171-184. doi: 10.1097/CMR.0000000000000436.

PMID:
29521881
6.

Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells.

Spear TT, Wang Y, Smith TW Jr, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI.

Mol Ther. 2018 Apr 4;26(4):996-1007. doi: 10.1016/j.ymthe.2018.01.015. Epub 2018 Feb 2.

PMID:
29503203
7.

N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.

Scheffel MJ, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI, Voelkel-Johnson C.

Cancer Immunol Immunother. 2018 Apr;67(4):691-702. doi: 10.1007/s00262-018-2120-5. Epub 2018 Feb 2.

PMID:
29396710
8.

TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.

Spear TT, Foley KC, Garrett-Mayer E, Nishimura MI.

J Leukoc Biol. 2018 May;103(5):973-983. doi: 10.1002/JLB.5A0817-314R. Epub 2018 Jan 19.

PMID:
29350789
9.

Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.

PMID:
29264697
10.

Cell intrinsic characteristics of human cord blood naïve CD4T cells.

Jacks RD, Keller TJ, Nelson A, Nishimura MI, White P, Iwashima M.

Immunol Lett. 2018 Jan;193:51-57. doi: 10.1016/j.imlet.2017.11.011. Epub 2017 Nov 24.

PMID:
29180044
11.

Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.

Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, Bronte V, Ugel S.

Oncotarget. 2017 May 23;8(50):86987-87001. doi: 10.18632/oncotarget.18115. eCollection 2017 Oct 20.

12.

CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.

Chatterjee S, Daenthanasanmak A, Chakraborty P, Wyatt MW, Dhar P, Selvam SP, Fu J, Zhang J, Nguyen H, Kang I, Toth K, Al-Homrani M, Husain M, Beeson G, Ball L, Helke K, Husain S, Garrett-Mayer E, Hardiman G, Mehrotra M, Nishimura MI, Beeson CC, Bupp MG, Wu J, Ogretmen B, Paulos CM, Rathmell J, Yu XZ, Mehrotra S.

Cell Metab. 2018 Jan 9;27(1):85-100.e8. doi: 10.1016/j.cmet.2017.10.006. Epub 2017 Nov 9.

13.

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.

PMID:
29052782
14.

Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms.

Muller L, Simms P, Hong CS, Nishimura MI, Jackson EK, Watkins SC, Whiteside TL.

Oncoimmunology. 2017 Jul 19;6(8):e1261243. doi: 10.1080/2162402X.2016.1261243. eCollection 2017.

15.

Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer.

Wrangle J, Paulos CM, Smith TW Jr, Nishimura MI, Rubinstein MP.

Mol Ther. 2017 Sep 6;25(9):1995-1996. doi: 10.1016/j.ymthe.2017.08.002. Epub 2017 Aug 19. No abstract available.

16.

Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells.

Spear TT, Wang Y, Foley KC, Murray DC, Scurti GM, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI.

Cancer Immunol Immunother. 2017 Nov;66(11):1411-1424. doi: 10.1007/s00262-017-2032-9. Epub 2017 Jun 20.

PMID:
28634816
17.

HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer.

Foley KC, Spear TT, Murray DC, Nagato K, Garrett-Mayer E, Nishimura MI.

Mol Ther Oncolytics. 2017 May 17;5:105-115. doi: 10.1016/j.omto.2017.05.004. eCollection 2017 Jun 16.

18.

How an alloreactive T-cell receptor achieves peptide and MHC specificity.

Wang Y, Singh NK, Spear TT, Hellman LM, Piepenbrink KH, McMahan RH, Rosen HR, Vander Kooi CW, Nishimura MI, Baker BM.

Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4792-E4801. doi: 10.1073/pnas.1700459114. Epub 2017 Jun 1.

19.

Comparative exploration of multidimensional flow cytometry software: a model approach evaluating T cell polyfunctional behavior.

Spear TT, Nishimura MI, Simms PE.

J Leukoc Biol. 2017 Aug;102(2):551-561. doi: 10.1189/jlb.6A0417-140R. Epub 2017 May 26.

PMID:
28550117
20.

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.

Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH, Thomas MB, Paulos CM, Salazar AM, Nishimura MI, Rubinstein MP, Li Z, Cole DJ.

J Hematol Oncol. 2017 Apr 7;10(1):82. doi: 10.1186/s13045-017-0459-2.

21.

Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.

Kesarwani P, Chakraborty P, Gudi R, Chatterjee S, Scurti G, Toth K, Simms P, Husain M, Armeson K, Husain S, Garrett-Mayer E, Vasu C, Nishimura MI, Mehrotra S.

Oncotarget. 2016 Oct 25;7(43):69371-69383. doi: 10.18632/oncotarget.12674.

22.

Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.

Scheffel MJ, Scurti G, Simms P, Garrett-Mayer E, Mehrotra S, Nishimura MI, Voelkel-Johnson C.

Cancer Res. 2016 Oct 15;76(20):6006-6016.

23.

Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

Banerjee A, Thyagarajan K, Chatterjee S, Chakraborty P, Kesarwani P, Soloshchenko M, Al-Hommrani M, Andrijauskaite K, Moxley K, Janakiraman H, Scheffel MJ, Helke K, Armenson K, Palanisamy V, Rubinstein MP, Mayer EG, Cole DJ, Paulos CM, Christina-Voelkel-Johnson, Nishimura MI, Mehrotra S.

Cancer Res. 2016 Sep 15;76(18):5229-5240. doi: 10.1158/0008-5472.CAN-15-1798. Epub 2016 Jul 27.

24.

Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.

Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S.

Cancer Res. 2016 May 1;76(9):2540-51. doi: 10.1158/0008-5472.CAN-15-2318.

25.

Strategies to genetically engineer T cells for cancer immunotherapy.

Spear TT, Nagato K, Nishimura MI.

Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2. Review.

26.

Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC, Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI.

J Leukoc Biol. 2016 Sep;100(3):545-57. doi: 10.1189/jlb.2A1215-561R. Epub 2016 Feb 26.

27.

Differential scanning fluorimetry based assessments of the thermal and kinetic stability of peptide-MHC complexes.

Hellman LM, Yin L, Wang Y, Blevins SJ, Riley TP, Belden OS, Spear TT, Nishimura MI, Stern LJ, Baker BM.

J Immunol Methods. 2016 May;432:95-101. doi: 10.1016/j.jim.2016.02.016. Epub 2016 Feb 18.

28.

How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoire.

Blevins SJ, Pierce BG, Singh NK, Riley TP, Wang Y, Spear TT, Nishimura MI, Weng Z, Baker BM.

Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1276-85. doi: 10.1073/pnas.1522069113. Epub 2016 Feb 16.

29.

TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.

Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, Foley KC, Murray DC, Scurti GM, Li M, Thomas JT, Langerman A, Garrett-Mayer E, Zhang Y, Nishimura MI.

Cancer Immunol Immunother. 2016 Mar;65(3):293-304. doi: 10.1007/s00262-016-1800-2. Epub 2016 Feb 3.

30.

Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.

Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC.

Pigment Cell Melanoma Res. 2016 May;29(3):379-84. doi: 10.1111/pcmr.12458. Epub 2016 Mar 4.

31.

Cutting Edge: AhR Is a Molecular Target of Calcitriol in Human T Cells.

Takami M, Fujimaki K, Nishimura MI, Iwashima M.

J Immunol. 2015 Sep 15;195(6):2520-3. doi: 10.4049/jimmunol.1500344. Epub 2015 Aug 14.

32.

FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.

You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G, Nand S, Breuer EK, Kuo PC, Breslin P, Kini AR, Nishimura MI, Zeleznik-Le NJ, Zhang J.

Cell Rep. 2015 Mar 31;10(12):2055-68. doi: 10.1016/j.celrep.2015.02.056. Epub 2015 Mar 19.

33.

Promoting thiol expression increases the durability of antitumor T-cell functions.

Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, Fang Q, Naga OS, Simms P, Beeson G, Voelkel-Johnson C, Garrett-Mayer E, Beeson CC, Nishimura MI, Mehrotra S.

Cancer Res. 2014 Nov 1;74(21):6036-6047. doi: 10.1158/0008-5472.CAN-14-1084. Epub 2014 Aug 27.

34.

Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Longley BJ, Engelhard VH, Mehrotra S, Le Poole IC.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1075-85. doi: 10.1111/pcmr.12284. Epub 2014 Jul 21.

35.

A quantitative increase in regulatory T cells controls development of vitiligo.

Chatterjee S, Eby JM, Al-Khami AA, Soloshchenko M, Kang HK, Kaur N, Naga OS, Murali A, Nishimura MI, Caroline Le Poole I, Mehrotra S.

J Invest Dermatol. 2014 May;134(5):1285-1294. doi: 10.1038/jid.2013.540. Epub 2013 Dec 23.

36.

Mutant HSP70 reverses autoimmune depigmentation in vitiligo.

Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC.

Sci Transl Med. 2013 Feb 27;5(174):174ra28. doi: 10.1126/scitranslmed.3005127.

37.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

38.

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.

Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI.

J Immunol. 2012 Aug 15;189(4):1627-38. doi: 10.4049/jimmunol.1103271. Epub 2012 Jul 13.

39.

Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.

Al-Khami AA, Mehrotra S, Nishimura MI.

Self Nonself. 2011 Apr;2(2):80-84. Epub 2011 Apr 1.

40.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

41.

Structure-activity relationship of T-cell receptors based on alanine scanning.

Narimatsu S, Yoshioka Y, Morishige T, Yao X, Tsunoda S, Tsutsumi Y, Nishimura MI, Mukai Y, Okada N, Nakagawa S.

Biochem Biophys Res Commun. 2011 Dec 2;415(4):558-62. doi: 10.1016/j.bbrc.2011.10.092. Epub 2011 Oct 31.

PMID:
22079637
42.

CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression.

Zloza A, Jagoda MC, Lyons GE, Graves MC, Kohlhapp FJ, O'Sullivan JA, Lacek AT, Nishimura MI, Guevara-Patiño JA.

Cancer Immunol Immunother. 2011 Feb;60(2):291-7. doi: 10.1007/s00262-010-0962-6. Epub 2010 Dec 31.

43.

Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity.

McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, Gretch DR, Rosen HR.

J Clin Invest. 2010 Dec;120(12):4546-57. doi: 10.1172/JCI43127. Epub 2010 Nov 15. Erratum in: J Clin Invest. 2011 Feb 1;121(2):821.

44.

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R.

Int J Cancer. 2011 Jan 15;128(2):390-401. doi: 10.1002/ijc.25613. Epub 2010 Oct 13.

45.

Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity.

Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T, Heemskerk MH, Rosen HR, Nishimura MI.

PLoS Pathog. 2010 Jul 29;6(7):e1001018. doi: 10.1371/journal.ppat.1001018.

46.

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA.

PLoS One. 2010 Jul 22;5(7):e11726. doi: 10.1371/journal.pone.0011726.

47.

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.

Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14286-91. doi: 10.1073/pnas.1008300107. Epub 2010 Jul 12.

48.

Reduced skin homing by functional Treg in vitiligo.

Klarquist J, Denman CJ, Hernandez C, Wainwright DA, Strickland FM, Overbeck A, Mehrotra S, Nishimura MI, Le Poole IC.

Pigment Cell Melanoma Res. 2010 Apr;23(2):276-86. doi: 10.1111/j.1755-148X.2010.00688.x. Epub 2010 Feb 19. Erratum in: Pigment Cell Melanoma Res. 2010 Jun;23(3):477. Wainwright, Derek J [corrected to Wainwright, Derek A].

49.

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, Orentas R, Guevara-Patiño J, Nishimura MI.

Cancer Immunol Immunother. 2010 Jun;59(6):851-62. doi: 10.1007/s00262-009-0810-8. Epub 2010 Jan 6.

50.

Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.

Klarquist J, Barfuss A, Kandala S, Reust MJ, Braun RK, Hu J, Dilling DF, McKee MD, Boissy RE, Love RB, Nishimura MI, Le Poole IC.

Am J Pathol. 2009 Dec;175(6):2463-72. doi: 10.2353/ajpath.2009.090525. Epub 2009 Nov 5.

Supplemental Content

Loading ...
Support Center